{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-108952","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-09-18T20:30:44+00:00","discovered_at":"2026-09-18T20:31:06.579078+00:00","generated_at":"2026-09-18T20:31:14.439072+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Outlook Therapeutics sets LYTENAVA US wholesale acquisition cost at $485/vial","bullets":["On Sep 16, 2026, Outlook Therapeutics established LYTENAVA WAC at $485 per vial in the US.","Pricing applies to LYTENAVA, the company's ophthalmic product; no patient volumes or revenue disclosed.","WAC is the base wholesale list price; may affect reimbursement and distribution economics.","No guidance, clinical data, or launch-date details included in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-108952","json":"https://secwatch.observer/filing/0001104659-26-108952.json","markdown":"https://secwatch.observer/filing/0001104659-26-108952.md","text":"https://secwatch.observer/filing/0001104659-26-108952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/0001104659-26-108952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T20:31:14.439072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}